[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cerebrovascular-accident-cva\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cerebrovascular-accident-cva":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,50,85,119,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100600317","respark---brain-q-for-chronic-stroke-100600317",false,"NCT07095920","RESPARK - Brain Q for Chronic Stroke","Frequency-tuned Electromagnetic Field Treatment to Facilitate Recovery of Patients With Chronic Stroke","Inclusion Criteria:\n\n1. Upper Extremity Fugl-Meyer Assessment score between 22-50 (inclusive) of impaired limb.\n2. Upper Extremity Fugl-Meyer Assessment score is within up to 3-point difference between Screening and Baseline visit.\n3. Age 18 to 80 years of age (inclusive).\n4. Stroke due to ischemia or to intracerebral hemorrhage.\n5. \\>6 months to 5 years from stroke onset.\n6. Box \\& Block Test score with affected arm is ≥1 block in 60 seconds.\n7. Able to sit with the investigational system for 40 consecutive minutes.\n8. Can follow a 3-step command, such as \"take the paper, fold it in half, and return it to me\", or a non-verbal equivalent.\n9. Willingness to participate in physical exercises during study intervention sessions.\n10. Availability of a relative or other caregiver that is able to participate in training and assist during treatment sessions at Brooks and home during the study duration.\n11. If female, not pregnant or breastfeeding or planning pregnancy during the study period.\n12. The subject is able to provide Informed consent.\n\nExclusion Criteria:\n\n1. Severe neglect impairment interfering with assessments or treatments.\n2. Severe depression, defined as Geriatric Depression Scale (GDS) Score \\>10\u002F15\n3. Presence of implanted or retained MR-incompatible devices or materials, or the presence of life-sustaining MR-compatible devices (e.g. pacemaker or internal cardiac defibrillator).\n4. Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years\n5. Botulinum toxin to the paretic arm: received in the prior 3 months OR expected before the 6-Month Visit\n6. Severe upper extremity spasticity, defined as presence of contracture or modified Ashworth Scale score ≥3 in either biceps or pectoralis\n7. Pre-existing neurological condition (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and\u002For confound neurological or functional evaluation.\n8. Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and\u002For confound neurological or functional evaluation.\n9. Unstable serious illness\u002Fcondition (e.g., active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.\n10. Alcohol abuse and\u002For illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.\n11. Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.\n12. Active participation in an upper extremity rehabilitation program provided by a licensed provider within 4 weeks from the screening visit and until the primary endpoint visit.\n13. Employee of the Sponsor.\n14. Prisoner.","ALL","18 Years","80 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","This trial tests a promising new intervention to promote post-stroke neural reorganization and functional recovery. The Q Therapeutic (BQ 3.0) is a wearable medical system that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. This trial is a prospective, single-arm, open-label, single center clinical trial designed to evaluate the safety, feasibility, and efficacy of the Q Therapeutic (BQ 3.0) System in the rehabilitation of people with chronic stroke.",[27,28,29],"Stroke","Chronic Stroke Patients","Cerebrovascular Accident (CVA)",[31,32,33,34,35,36],"BrainQ","Electromagnetic Stimulation","upper extremity","rehabilitation","exercise","mobility","RECRUITING","2026-07-01",{"date":40,"type":41},"2026-07-02","ACTUAL",{"date":43,"type":41},"2025-08-27",{"date":45,"type":21},"2026-12",{"name":47,"class":48},"University of Florida","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":4},"100639799","phase-1-investigating-central-contributions-to-fatigue-using-non-invasive-brain-stimulation-100639799","NCT07613970","Investigating Central Contributions to Fatigue Using Non-invasive Brain Stimulation","Investigating the Causal Contribution of Neural Oscillations to Neuromuscular Fatigue After Stroke Using tACS","Inclusion Criteria:\n\nFirst-ever stroke\n\n≥18 years Subacute phase: 1 week to 6 months post-stroke Quadriceps (hemiplegic side) strength ≤3\u002F5 (Medical Research Council (MRC)) Montreal Cognitive Assessment (MoCA) ≥21\n\nExclusion Criteria:\n\nHistory of a previous stroke Severe spasticity (Modified Ashworth Scale (MAS) 3-4 in quadriceps\u002Fhamstrings) Other neurological, motor, musculoskeletal, or orthopedic conditions affecting trunk stability and lower limb mobility Non-cerebral strokes (e.g., brainstem, cerebellar), or dementia (MoCA ≤20) Current or former athletes. Athletes are defined as individuals who participated in organized competitive sports and engaged in structured training ≥3 sessions per week for ≥1 year within the 5 years preceding stroke Contraindications for tACS (e.g., presence of a deep brain stimulator, pacemaker, head wound, etc.).",true,{"count":59,"type":21},120,[61,62],"PHASE1","PHASE2","The goal of this interventional study is to understand the contribution of the central components to the manifestation of neuromuscular fatigue in stroke survivors. The study will include adults with a first-ever stroke in the subacute phase.\n\nThe main question it aims to answer:\n\n• How does the brain activity contribute to the manifestation of neuromuscular fatigue in stroke survivors?\n\nResearchers will compare stroke participants receiving active vs sham tACS in a single session before the fatiguing contractions to determine whether central changes can influence fatigue onset\u002Fprogression.\n\nParticipants will:\n\n* Perform repeated leg muscle contractions until fatigue while seated in an experimental setup\n* Receive either active or sham tACS for 20 minutes before the fatiguing contractions.\n* Wear non-invasive sensors to record brain activity (EEG) and muscle activity (EMG) during the task\n* Complete the study during a single experimental session in which fatigue-related changes will be measured throughout the task",[27,29,65,66],"Ischemia Stroke","Hemorrhage Stroke",[68,69,70,71,72,73,74],"fatigue","electroencephalography","EEG","electromyography","EMG","transcranial alternating current stimulation","tACS","NOT_YET_RECRUITING","2026-05-21",{"date":78,"type":41},"2026-05-29",{"date":80,"type":21},"2026-09-01",{"date":82,"type":21},"2029-10-31",{"name":84,"class":48},"Vrije Universiteit Brussel",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":97,"conditions":98,"keywords":101,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":49},"100352577","rtms-plus-ccfes-mediated-functional-task-practice-for-severe-stroke-100352577","NCT03870672","rTMS Plus CCFES-mediated Functional Task Practice for Severe Stroke","Contralaterally Controlled FES Combined With Brain Stimulation for Severe Upper Limb Hemiplegia","rTMS+CCFES","Inclusion Criteria:\n\n* age 18 to 90 years old at time of randomization\n* greater than 6 months since a first clinical cortical or subcortical, ischemic or hemorrhagic stroke\n* severe upper limb hemiparesis defined as less than 10° active wrist extension or less than 10° active thumb abduction\u002Fextension or less than 10° active extension in at least two additional digits (i.e., will not meet minimum CIMT criteria)\n* ability to follow 3-stage commands and can remember 2 items from a list of 3 items after 3 minutes\n* adequate active movement of shoulder and elbow to position the paretic hand on one's lap for performance of functional task practice and CCFES-assisted hand opening exercises\n* skin intact on hemiparetic arm\n* surface electrical stimulation of the paretic finger and thumb extensors produces functional hand opening without pain\n* able to hear and respond to cues from stimulator\n* completed occupational therapy at least 2 months prior to enrollment (no concomitant OT)\n* full volitional hand opening\u002Fclosing of the non-paretic hand\n* ability to follow instructions for putting on and operating the CCFES stimulator or a caregiver available to provide assistance\n\nExclusion Criteria:\n\n* metal implant in the head\n* history of seizures as an adult\n* history of alcohol or substance abuse less than 10yrs prior to enrollment\n* intake of anticonvulsants or anti-depressants contraindicated with TMS\n* cardiac pacemaker or other programmable implant","90 Years",{"count":95,"type":21},72,[24],"This study is a necessary and important step in the development of a new therapy for upper limb functional recovery in patients with severe motor impairment. It is the first clinical trial of non-invasive brain stimulation (repetitive transcranial magnetic stimulation or rTMS) delivered to excite the undamaged hemisphere (specifically the contralesional higher motor cortices or cHMC) in stroke. Therefore, this study will determine whether the positive results obtained in our short-term pilot study can be made to last longer and produce functional benefits in severe patients with the application of brain stimulation in combination with long-term rehabilitation therapy. Rehabilitation therapy administered is called contralaterally controlled functional electrical stimulation (CCFES). Determining whether combining rTMS facilitating the cHMC with CCFES produces synergistic gains in functional abilities in severe patients is necessary for acceptance by the clinical community and to move this technology toward commercialization and widespread dissemination. The proposed study will determine whether the combination of rTMS facilitating the cHMC with CCFES produces greater improvements in upper extremity function in severe participants who are ≥6 months from stroke onset than the combination of rTMS facilitating the damaged hemisphere (specifically the ipsilesional primary motor cortex, iM1) and CCFES or the combination of sham rTMS and CCFES. The secondary purposes are to define which patients benefit most from the treatments, which may inform future device and treatment development and clinical translation, and to explore what distinct effects the three treatments have on the brain. To accomplish these purposes, we are conducting a clinical trial that enrolls severe stroke patients.",[27,99,29,100],"Hemiplegia","Hemiparesis",[102,27,103,104,105,106,107,108,109],"Upper limb","CVA","Rehabilitation","Brain Stimulation","CCFES","Motor Cortex","TMS","Motor Recovery","2026-03-20",{"date":112,"type":41},"2026-03-24",{"date":114,"type":41},"2019-05-14",{"date":116,"type":21},"2026-12-31",{"name":118,"class":48},"The Cleveland Clinic",{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":134,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":49},"100591364","q-therapeutic-system-for-chronic-stroke-recovery-100591364","NCT06979466","Q Therapeutic System for Chronic Stroke Recovery","Facilitation Recovery For Patients With Chronic Stroke: The Q Therapeutic System, Frequency-Tuned Electromagnetic Field Treatment","EMAGINE-C","Inclusion Criteria:\n\n* FMA-UE score between 22-50 (inclusive) of impaired limb.\n* Difference between Screening and Baseline visit FMA-UE is 3 points or fewer.\n* Age 18 to 80 years of age (inclusive).\n* Stroke due to ischemia or to intracerebral hemorrhage.\n* \\>6 months to 5 years from index stroke onset.\n* Box \\& Block Test score with affected arm is ≥1 block in 60 seconds at Baseline Visit.\n* Able to sit with the investigational System for 40 consecutive minutes.\n* Can follow a 3-step command, such as \"take the paper, fold it in half, and return it to me\", or a non-verbal equivalent.\n* Willingness to participate in physical exercises during study intervention sessions.\n* Availability of a relative or other caregiver able to assist during study treatment sessions and visits.\n* If female, not pregnant or breastfeeding or planning pregnancy during the study period.\n* Informed consent signed by subject.\n\nExclusion Criteria:\n\n* Severe neglect impairment interfering with assessments or treatments.\n* Severe depression, defined as GDS Score \\>10\u002F15\n* The presence of MR-incompatible implanted devices or MR-incompatible retained objects; or the presence of life-sustaining MR-compatible devices (e.g. pacemaker or internal cardiac defibrillator).\n* Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years\n* Botulinum toxin to the paretic arm: received in the prior 3 months OR expected before the 6-Month Visit\n* Severe UE spasticity, defined as presence of upper extremity contracture or modified Ashworth Scale score≥3 in either biceps or pectoralis\n* Pre-existing neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and\u002For confound neurological or functional evaluation.\n* Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and\u002For confound neurological or functional evaluation.\n* Unstable serious illness\u002Fcondition (eg, active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.\n* Alcohol abuse and\u002For illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.\n* Participation in another interventional trial that would conflict with the current study or clinical endpoint interference may occur.\n* Participation in an upper extremity rehabilitation program provided by a licensed provider in the 4 weeks prior to the Screening visit, or a or planned participation in such program at any time between the Screening Visit and the primary endpoint visit.\n* Employee of the Sponsor.\n* Prisoner.",{"count":20,"type":21},[24],"Evaluate the effectiveness of the Q Therapeutic (BQ 3.0) System for individuals with chronic stroke in improving upper extremity function as determined by change in functional outcome measures after 3-month treatment, including in-clinic and at-home sessions.",[27,131,132,29,133],"Hemorrhage","Brain Injury","Chronic Stroke Patient",[31,27,135,32],"Cerebrovascular Disorders","2025-08-07",{"date":138,"type":41},"2025-08-12",{"date":140,"type":41},"2025-05-26",{"date":142,"type":21},"2026-06-30",{"name":144,"class":48},"Burke Rehabilitation Hospital",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":49},"100570727","effectiveness-of-enhanced-external-counterpulsation-for-post-acute-stroke-patients-100570727","NCT06711003","Effectiveness of Enhanced External Counterpulsation for Post-acute Stroke Patients","Inclusion Criteria:\n\n* Patients with acute cerebrovascular disease, within 1 month after acute attack.\n* Stable medical condition: (1). Neurological condition: The neurological condition has not deteriorated for more than 72 hours. (2). Vital signs including blood pressure, heartbeat, and body temperature are stable or controllable for more than 72 hours. (3). No complications such as infection, blood abnormalities, gastrointestinal bleeding, or stable or controllable after treatment.\n* Those whose functional status is moderate to moderately severe functional impairment (MRS 3-4) and who are judged by the medical team to have active rehabilitation potential: (1). Have basic cognition, learning ability and willingness. (2) Have sufficient physical strength: able to maintain a sitting position on a wheelchair or bed edge for at least one hour with support. (3). Be able to actively participate in rehabilitation treatment plans.\n* Aged over 20 years old\n\nExclusion Criteria:\n\n* Patients with atrial fibrillation\u002Farrhythmia.\n* Within 2 weeks after cardiac catheterization or arterial puncture at the femoral artery puncture site.\n* Decompensated heart failure (NYHA class 3 or 4).\n* Left ventricular ejection fraction (EF) \\\u003C 30%.\n* Moderate or severe aortic regurgitation.\n* Persistent and uncontrolled hypertension (blood pressure persistently \\>160\u002F100 mmHg).\n* Bleeding tendency.\n* Active phlebitis\u002Fvenous disease of the lower extremities.\n* Severe vascular occlusive disease of the lower extremities.\n* The presence of documented aortic aneurysm\u002Fdissection requiring surgical repair.\n* Pregnancy.","20 Years",{"count":153,"type":21},110,[24],"The goal of this clinical trial is to learn if there benefits combine enhanced external counterpulsation (EECP) with the standard post-acute care (PAC) rehabilitation treatment to treat stroke patients.. The main questions it aims to answer are:\n\nWhat is the feasibility of combining EECP and PAC? Does EECP combined PAC rehabilitation improve functional outcomes of post-stroke patients? Researchers will compare standard PAC rehabilitation and EECP combined PAC rehabilitation to see if EECP has benefits to treat stroke.",[29],[29,158,159],"enhanced external counterpulsation","post-acute care","2024-11-27",{"date":162,"type":41},"2024-12-02",{"date":164,"type":41},"2024-10-22",{"date":166,"type":21},"2025-05-15",{"name":168,"class":48},"China Medical University Hospital"]